Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Revenue: 2019-2025

Historic Revenue for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $2.8 million.

  • Kymera Therapeutics' Revenue fell 26.12% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238,000, marking a year-over-year decrease of 100.27%. This contributed to the annual value of $3.1 million for FY2024, which is 96.06% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Revenue is $2.8 million, which was down 75.91% from $11.5 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Revenue high stood at $47.9 million for Q4 2023, and its period low was -$36.6 million during Q4 2024.
  • For the 3-year period, Kymera Therapeutics' Revenue averaged around $10.7 million, with its median value being $10.3 million (2024).
  • Per our database at Business Quant, Kymera Therapeutics' Revenue spiked by 463.23% in 2021 and then tumbled by 176.39% in 2024.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Revenue stood at $15.3 million in 2021, then grew by 5.66% to $16.1 million in 2022, then skyrocketed by 196.70% to $47.9 million in 2023, then plummeted by 176.39% to -$36.6 million in 2024, then dropped by 26.12% to $2.8 million in 2025.
  • Its Revenue was $2.8 million in Q3 2025, compared to $11.5 million in Q2 2025 and $22.1 million in Q1 2025.